Zhitong Financial APP learned that Betters Medical Investment Holdings Limited (Pak Tak Healthcare Investment Holdings Limited) was heard through the Hong Kong Stock Exchange, with Bank of China International and Sino-Thai International as its co-sponsors, according to the Hong Kong Stock Exchange on September 15.

It is reported that$BETTERS MEDICAL INVESTMENT (810180.HK)$Is one of China's leading developers and providers of microwave ablation (microwave ablation) medical devices for minimally invasive tumor treatment. the company's product supply and pipeline products mainly include microwave ablation therapeutic instruments and microwave ablation needles used in conjunction with therapeutic instruments.

The company's proprietary microwave ablation medical devices are used to treat benign and malignant tumors with increasing incidence in China, including thyroid nodules, liver cancer, lung cancer and breast nodules. According to Frost Sullivan, in terms of sales revenue and sales volume of microwave ablation needles in 2021, the company is the largest supplier of microwave ablation medical devices for the treatment of thyroid and breast nodules in China. In addition, in terms of sales revenue in 2021, the company is the third largest supplier of microwave ablation medical devices in China. At the same time, the company is also the first company in China to specialize in the treatment of thyroid nodules with proprietary microwave ablation medical devices and successfully registered as the third category of medical devices. On the last feasible date, the company has obtained the third type of medical device registration certificate for microwave ablation of medical devices for liver cancer and thyroid nodules.

The company operates in the microwave ablation medical device market, which still lacks services in China but is growing rapidly and has great potential for growth. According to Frost Sullivan, the number of microwave ablation operations in China increased from 70900 in 2016 to 181200 in 2021, and is expected to reach 660000 in 2026, with a compound annual growth rate of 29.6% from 2022 to 2026. In addition, in terms of hospital charges, the size of China's microwave ablation market is expected to increase significantly from 3 billion yuan in 2022 to 9.2 billion yuan in 2026, with a compound annual growth rate of 32.5%. As one of the leading suppliers of microwave ablation medical devices in China, the company believes that it is in a good position in the market, taking advantage of the positive trends in the microwave ablation market (such as the increasing number of tumor patients, the expansion of indications for microwave ablation and the increasing number of hospitals that can perform microwave ablation surgery) to further consolidate the company's position in China's microwave ablation market.

In addition, with the company's solid and strategically managed network of distributors and distributors, coupled with close cooperation with medical associations and doctors through sales and marketing work, the company has been promoting the benefits of microwave ablation therapy to medical practitioners in China. Therefore, more and more hospitals choose microwave ablation to treat tumor patients. The number of Chinese hospitals purchasing the company's products increased from 258 in fiscal year 2019 to 303 in fiscal year 2021, of which the number of tertiary A hospitals and tertiary B hospitals increased from 149to 177. The company's products are finally sold to the hospital by the following ways: directly or through the distributor to the hospital, or to the dealer, and then the dealer is authorized by the company to resell the product to the designated hospital. With the company's solid and strategically managed dealer network, benefiting from the improved channels and resources of the company's dealers, it can save the cost and time required to launch and sell products in the target market.

Financially, the company's earnings in 2019, 2020, 2021 and the first five months of 2022 were approximately 85.029 million yuan, 118 million yuan, 189 million yuan and 63.764 million yuan, respectively.